The antiproliferative effect induced by chloroquine 2.5 μM among the various patients showed no significant association with differentiation (FAB classification, CD34 expression), karyotype, NPM1 or FLT3 mutations), and it did not differ between patients with secondary and de novo AML (data not shown). This evidence concerns the gene FLT3 and acute myeloid leukemia.